{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-009564","form_type":"8-K","ticker":"ABEO","cik":"0000318306","company_name":"ABEONA THERAPEUTICS INC.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:50.927714+00:00","generated_at":"2026-05-22T00:48:17.537337+00:00","sec_items":["1.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Abeona Therapeutics sells PRV for $155M cash; expects profitability early 2026","bullets":["Definitive agreement to sell Rare Pediatric Disease PRV for $155M in gross cash proceeds at closing.","PRV awarded by FDA on April 28, 2025 upon approval of ZEVASKYN (prademagene zamikeracel) for RDEB.","CFO: proceeds provide over two years of operating expenses without additional financing; ZEVASKYN launch Q3 2025.","Expects profitability in early 2026; closing subject to HSR waiting period; Stifel and Jefferies as advisors."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-009564","json":"https://secwatch.observer/filing/0001641172-25-009564.json","markdown":"https://secwatch.observer/filing/0001641172-25-009564.md","text":"https://secwatch.observer/filing/0001641172-25-009564.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/0001641172-25-009564-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/318306/000164117225009564/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T00:48:17.537337+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}